Practice 6 structured short- and long-answer medical questions on Lung Pathology — Must-Know. Review model answers for exam revision.
Answer: This document provides a comprehensive overview of lung pathology, covering normal lung structure, common conditions like atelectasis and ARDS, and detailed explanations of obstructive and restrictive lung diseases. It delves into specific obstructive conditions such as emphysema, chronic bronchitis, asthma, and bronchiectasis, and examines various chronic interstitial lung diseases including idiopathic pulmonary fibrosis, pneumoconioses (coal dust, silica, asbestos), sarcoidosis, hypersensitivity pneumonitis, pulmonary eosinophilia, and smoking-related interstitial diseases. The text also addresses pulmonary vascular diseases, focusing on pulmonary embolism, pulmonary hypertension, and diffuse alveolar haemorrhage syndromes. Finally, it details a wide range of pulmonary infections, from community-acquired bacterial and viral pneumonias to hospital-acquired, aspiration, and abscess formations, with specific sections on tuberculosis, nontuberculous mycobacteria, fungal infections, pneumonia in immunocompromised hosts, and pulmonary disease in HIV. ## Key Points - **Acinus**: The functional unit of the lung distal to the terminal bronchiole, responsible for gas exchange. - **Atelectasis**: Loss of lung volume due to inadequate expansion of air spaces, potentially reversible except for contraction atelectasis. - **ARDS (Acute Respiratory Distress Syndrome)**: Severe lung injury characterized by diffuse alveolar damage, hypoxemia, and non-cardiogenic pulmonary edema. - **Obstructive Lung Disease**: Characterized by increased resistance to airflow, leading to a decreased FEV1/FVC ratio (e.g., emphysema, asthma). - **Restrictive Lung Disease**: Characterized by reduced lung expansion, leading to a reduced FVC with a near-normal FEV1/FVC ratio (e.g., IPF, sarcoidosis). - **Emphysema**: Permanent enlargement of air spaces distal to terminal bronchioles with alveolar wall destruction. - **Chronic Bronchitis**: Defined clinically by a persistent productive cough for at least 3 months in 2 consecutive years, marked by mucus hypersecretion. - **Asthma**: Chronic inflammatory airway disorder with reversible obstruction, bronchial inflammation, and hyperreactivity, driven by TH2 cells and eosinophils. - **Bronchiectasis**: Permanent dilation of bronchi and bronchioles due to destruction of smooth muscle and elastic tissue, often secondary to persistent infection or obstruction. - **Idiopathic Pulmonary Fibrosis (IPF)**: A chronic, progressive interstitial lung disease of unknown etiology characterized by Usual Interstitial Pneumonia (UIP) pattern. - **Pneumoconioses**: Lung disorders caused by inhalation of mineral dusts, most commonly coal dust, silica, and asbestos. - **Sarcoidosis**: A multisystem disease characterized by noncaseating granulomatous inflammation in various organs. - **Hypersensitivity Pneumonitis**: An immunologically mediated inflammatory lung disease affecting alveoli, triggered by inhaled antigens. - **Pulmonary Embolism**: Blockage of pulmonary arteries, most commonly by thrombi from deep leg veins. - **Pulmonary Hypertension**: Elevated pulmonary arterial pressure, classified into five groups based on underlying causes. - **Diffuse Alveolar Haemorrhage Syndromes**: Conditions involving bleeding into the alveolar spaces, such as Goodpasture syndrome and Granulomatosis with Polyangiitis (GPA). - **Tuberculosis**: A communicable chronic granulomatous disease caused by Mycobacterium tuberculosis, characterized by granuloma formation and potential for cavitation. - **Pneumonia in Immunocompromised Host**: Increased susceptibility to opportunistic infections like Pneumocystis jiroveci, CMV, fungi, and atypical bacteria. ## Detailed Notes ### 1. Normal Lung Structure **Key concepts:** Airway anatomy · Acinus · Alveolar wall components · Cell types - The respiratory system develops as an outgrowth from the ventral wall of the foregut. - The right lung has 3 lobes and 3 main bronchi; the left lung has 2 lobes and 2 main bronchi. - Airways progress from bronchi to bronchioles (lacking cartilage and submucosal glands) to terminal bronchioles, and finally to the acinus. - The **acinus** is the part of the lung distal to the terminal bronchiole, consisting of respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli, which are the primary sites of gas exchange. **Alveolar Wall Components (Blood to Air):** - Capillary endothelium and its basement membrane. - Pulmonary interstitium, containing elastic fibers, collagen, fibroblasts, smooth muscle cells, mast cells, and mononuclear cells. - Alveolar epithelium: - **Type I pneumocytes**: Flat, plate-like cells covering 95% of the alveolar surface. - **Type II pneumocytes**: Rounded cells that synthesize surfactant and are crucial for repair after type I pneumocyte injury. - Alveolar macrophages: These cells reside freely in the alveolar space and can contain carbon particles in urban dwellers. ### 2. Atelectasis (Collapse) **Conditions covered:** Resorption · Compression · Contraction atelectasis - Atelectasis is the loss of lung volume caused by the inadequate expansion of air spaces. - It leads to ventilation-perfusion (V/Q) imbalance and hypoxia. - Except for contraction atelectasis, other forms are potentially reversible. **Three Forms:** **Resorption Atelectasis** - Occurs when an obstruction prevents air from reaching distal airways. The air distal to the obstruction is gradually absorbed, leading to alveolar collapse. - The most common cause is obstruction of a bronchus. - Causes include: postoperative mucous plugs, foreign body aspiration (especially in children), bronchial asthma, bronchiectasis, chronic bronchitis, and intrabronchial tumors (which may be the first sign of malignancy). **Compression Atelectasis** - Occurs due to the accumulation of fluid, blood, or air in the pleural cavity, which compresses the lung. - Causes include: pleural effusion (e.g., in congestive heart failure) and pneumothorax (air leakage into the pleural cavity). - Basal atelectasis can result from failure to breathe deeply, commonly seen in bedridden patients, those with ascites, or post-surgery. **Contraction Atelectasis (Cicatrization)** - Caused by local or diffuse fibrosis of the lung or pleura, which hampers lung expansion. - This form of atelectasis is irreversible. ### 3. Acute Respiratory Distress Syndrome (ARDS) **Key concepts:** DAD · Neutrophil-mediated injury · Hyaline membranes · Clinical course - ARDS is defined as respiratory failure occurring within one week of a known clinical insult, characterized by bilateral opacities on chest imaging that are not fully explained by effusions, atelectasis, cardiac failure, or fluid overload. - Severity is graded based on changes in arterial blood oxygenation. - **Most frequent triggers** include pneumonia (35–45%) and sepsis (30–35%), followed by aspiration, trauma, pancreatitis, and transfusion reactions. - **It is distinct from respiratory distress syndrome of the newborn**, which is caused by surfactant deficiency due to prematurity. **Pathogenesis** - The integrity of the alveolar-capillary membrane is compromised by endothelial and epithelial injury. - Within 30 minutes of an acute insult, pulmonary macrophages synthesize **IL-8**, a potent neutrophil chemotactic agent. - IL-8, IL-1, and TNF contribute to endothelial activation, leading to neutrophil sequestration and activation within pulmonary capillaries. - Activated neutrophils release **reactive oxygen species and proteases**, damaging the alveolar epithelium and endothelium. - This results in vascular leakiness and loss of surfactant, rendering the alveolar units unable to expand. - The outcome is determined by the balance between destructive forces and endogenous anti-proteases and anti-oxidants. **Morphology — Acute Phase** - Lungs appear dark red, firm, airless, and heavy. - Characterized by capillary congestion, necrosis of alveolar epithelial cells, and interstitial and intraalveolar edema and hemorrhage. - **Hyaline membranes** are the most characteristic finding, lining distended alveolar ducts and composed of fibrin-rich edema fluid and remnants of necrotic epithelial cells. - Collections of neutrophils are often seen in capillaries, especially in cases of sepsis. **Morphology — Organizing Stage** - Type II pneumocytes proliferate vigorously, attempting to regenerate the alveolar lining. - Fibrin-rich exudates organize into intraalveolar fibrosis. - There is marked thickening of the alveolar septa due to interstitial cell proliferation and collagen deposition. **Clinical Features** - Affects approximately 190,000 patients per year in the USA. - 85% of cases develop within 72 hours of the initial insult. - Overall hospital mortality is 38.5% (27% for mild, 32% for moderate, and 45% for severe ARDS). - Poor prognostic factors include advanced age, bacteremia, and multi-organ failure. - Survivors typically recover normal respiratory function within 6–12 months, though some may develop diffuse interstitial fibrosis. ### 4. Obstructive vs Restrictive Lung Disease **Key distinction — Pulmonary Function Tests:** | Feature | Obstructive | Restrictive | | :---------------- | :------------------------------- | :--------------------------------- | | **FVC** | Normal or slightly decreased | Reduced | | **FEV1** | Significantly decreased | Normal or reduced proportionately | | **FEV1/FVC ratio**| **Decreased** | **Near normal** | | **Mechanism** | Increased resistance to airflow | Reduced lung expansion | **Obstructive diseases:** Emphysema, Chronic bronchitis, Asthma, Bronchiectasis. **Restrictive diseases:** ARDS (acute), Pneumoconioses, IPF, Sarcoidosis (chronic); also chest wall disorders (obesity, pleural disease, neuromuscular disorders). ### 5. Obstructive Lung Diseases **Conditions covered:** Emphysema · Chronic Bronchitis · Asthma · Bronchiectasis #### Emphysema - Permanent enlargement of air spaces distal to the terminal bronchioles with destruction of their walls, occurring **without significant fibrosis**. - Classified based on its anatomic distribution within the acinus. **Four Types:** | Type | Location Affected | Association | | :------------------------ | :------------------------------------------------------ | :------------------------------------------------ | | Centriacinar (centrilobular) | Central/proximal acinus (respiratory bronchioles); distal alveoli spared | Cigarette smoking; upper lobes; most common | | Panacinar (panlobular) | Entire acinus uniformly enlarged | α1-antitrypsin deficiency; lower lobes | | Distal acinar (paraseptal) | Proximal acinus normal; distal part involved; adjacent to pleura and septa | Young adults; spontaneous pneumothorax; may form bullae | | Irregular | Acinus irregularly involved; associated with scarring | Healed inflammatory disease; clinically asymptomatic; possibly most common form | - Only **centriacinar and panacinar** emphysema cause significant airway obstruction. - Centriacinar is approximately 20 times more common than panacinar. **Pathogenesis — Key Mechanisms:** - Smoking and noxious particles trigger lung damage and inflammation, leading to parenchymal destruction. - **Protease-antiprotease imbalance**: Neutrophil and macrophage-derived proteases (like elastase) destroy connective tissue; deficiency of anti-proteases exacerbates this destruction. - **α1-antitrypsin deficiency**: Encoded by the Pi locus on chromosome 14; homozygous Z allele results in markedly decreased serum levels. Over 80% of affected individuals develop symptomatic panacinar emphysema, worsened by smoking. It accounts for approximately 1% of all emphysema cases. - **Oxidative stress**: Reactive oxygen species from cigarette smoke and activated macrophages/neutrophils cause additional tissue damage. - **Inflammatory mediators**: Leukotriene B4, IL-8, and TNF recruit neutrophils, macrophages, and CD4+/CD8+ T cells. - Airway infection is not an initiating factor but can cause acute exacerbations. - Loss of elastic tissue in alveolar walls reduces radial traction on small airways, leading to **airway collapse during expiration**, resulting in functional airflow obstruction. **Morphology:** - Panacinar emphysema: Lungs appear pale, voluminous, often obscuring the heart at autopsy. - Centriacinar emphysema: Lungs are deeper pink, less voluminous, with more severe involvement in the upper two-thirds. - Histology shows destruction of alveolar walls without fibrosis, leading to enlarged air spaces, diminished alveolar capillaries, and deformed terminal and respiratory bronchioles. - **Bullous emphysema**: Characterized by large subpleural blebs or bullae greater than 1 cm, which may rupture and cause pneumothorax. **Clinical Features:** - Dyspnea is the first and most prominent symptom, with insidious onset and steady progression. - Reduced FEV1 and normal/near-normal FVC result in a reduced FEV1/FVC ratio. - **"Pink puffers"**: Patients with pure emphysema, often barrel-chested, dyspneic, with prolonged expiration and a hunched-forward posture. They maintain adequate oxygenation until late stages and exhibit prominent hyperventilation. - **"Blue bloaters"**: Patients with emphysema plus chronic bronchitis. They experience less dyspnea, have CO2 retention, are hypoxic and cyanotic, and are often obese. They are prone to recurrent infections. - Secondary pulmonary hypertension can develop, leading to cor pulmonale (right-sided heart failure) in 20–30% of patients. - Death typically results from respiratory failure or right-sided heart failure. **Conditions Related to Emphysema:** - **Compensatory emphysema**: Dilation of residual alveoli after surgical removal of diseased lung or lobe. - **Obstructive overinflation**: Expansion of lung due to air trapping from subtotal airway obstruction, which can be life-threatening. - **Mediastinal (interstitial) emphysema**: Air enters the lung interstitium and tracks to the mediastinum and subcutaneous tissue. It can follow sudden increases in intraalveolar pressure (e.g., vomiting, violent coughing), whooping cough, or respirator use. Subcutaneous emphysema results in the patient "blowing up like a balloon" with crackling crepitation. #### Chronic Bronchitis - **Defined clinically**: Persistent productive cough for at least **3 consecutive months in at least 2 consecutive years**. - Common in cigarette smokers and urban dwellers, affecting 20–25% of men aged 40–65. **Pathogenesis:** - A distinctive feature is **hypersecretion of mucus beginning in the large airways**. - Cigarette smoking is the most important cause, along with irritants like sulfur dioxide and nitrogen dioxide. - Irritants lead to hypertrophy of mucous glands in the trachea and bronchi, and an increase in goblet cells in smaller bronchi and bronchioles. - Inflammation involves macrophages, neutrophils, and lymphocytes, but **not eosinophils** (unlike asthma). - Airflow obstruction arises from:
Answer: Model answer pending
Answer: - IL-13 from T cells and innate lymphoid cells plays a significant role in many effects, increasing mucin gene transcription and neutrophil elastase production in response to tobacco smoke. - Microbial infection plays a secondary role, perpetuating inflammation and exacerbating symptoms. **Morphology:** - The mucosal lining of larger airways is hyperemic, swollen, and covered by mucinous or mucopurulent secretions. - **Enlargement of mucus-secreting glands** is a diagnostic feature, assessed by the **Reid index** (ratio of submucosal gland thickness to bronchial wall thickness; normally ≤0.4, increased in chronic bronchitis). - Chronic bronchiolitis involves goblet cell metaplasia, mucous plugging, inflammation, and fibrosis. - In severe cases, complete obliteration of the lumen occurs, termed **bronchiolitis obliterans**. - Emphysematous changes often coexist. **Clinical Features:** - Some patients have persistent cough and sputum production without significant ventilatory dysfunction. - Others develop COPD with hypercapnia, hypoxemia, and cyanosis. - Frequent exacerbations lead to more rapid progression and poorer outcomes than emphysema alone. - Progressive disease can lead to pulmonary hypertension, cardiac failure, recurrent infections, and respiratory failure. #### Asthma - A chronic inflammatory disorder of the airways causing **recurrent episodes of wheezing, breathlessness, chest tightness, and cough** (particularly at night or early morning). - **Hallmarks**: Intermittent reversible airway obstruction, chronic bronchial inflammation with eosinophils, bronchial smooth muscle hypertrophy and hyperreactivity, and increased mucus secretion. - The incidence has increased significantly in Western countries over the past four decades. - The **hygiene hypothesis** suggests that reduced exposure to infectious organisms in early childhood may lead to defects in immune tolerance, predisposing to later hyperreactivity. **Types of Asthma:** **1. Atopic Asthma (most common)** - A classic Type I IgE-mediated hypersensitivity reaction. - Usually begins in childhood and is associated with a positive family history of atopy. - Triggered by allergens (dust, pollen, animal dander, food) or infections. - Skin testing with the offending antigen elicits an immediate wheal-and-flare reaction. - Driven by **TH2 cells**, with key cytokines including: - **IL-4 and IL-13**: Stimulate IgE production. - **IL-5**: Activates eosinophils. - **IL-13**: Stimulates mucus production. - IgE coats submucosal mast cells. Allergen exposure leads to mast cell degranulation, causing a **two-phase reaction**: - **Early (immediate) phase**: Bronchoconstriction, increased mucus, vasodilation; mediated by histamine, PGD2, leukotrienes (LTC4/D4/E4), and reflex neural pathways. - **Late phase**: Inflammatory response; chemokines (including eotaxin) recruit TH2 cells, eosinophils, and leukocytes, amplifying the inflammatory reaction. **2. Non-Atopic Asthma** - No evidence of allergen sensitization; skin tests are negative. - Triggered by viral infections (rhinovirus, parainfluenza) and inhaled pollutants (SO2, ozone, NO2). - Virus-induced inflammation lowers the threshold of subepithelial vagal receptors to irritants. - It shares the same ultimate mediators as atopic asthma and is treated similarly. **3. Drug-Induced Asthma** - **Aspirin** is a prominent example, inhibiting cyclo-oxygenase and leading to an abnormality in prostaglandin metabolism. - Presents with rhinitis, nasal polyps, urticaria, and bronchospasm. **4. Occupational Asthma** - Triggered by fumes (epoxy resins, plastics), organic/chemical dusts (wood, cotton, platinum), or gases (toluene). - Attacks develop after repeated exposure to the inciting antigen. **Airway Remodeling**: Structural changes occur from repeated bouts of inflammation, including: - Hypertrophy of bronchial smooth muscle and mucous glands. - Increased vascularity. - Subepithelial collagen deposition. - These changes can occur years before symptoms begin. **Morphology (fatal/biopsy cases):** - Lungs are distended due to air trapping, with small areas of atelectasis. - **Curschmann spirals**: Mucous plugs containing whorls of shed epithelium occluding bronchi/bronchioles. - **Charcot-Leyden crystals**: Crystalloids formed from eosinophil protein galectin-10. - Airway remodeling changes include: thickening of the airway wall, **sub-basement membrane fibrosis** (a characteristic finding), increased submucosal vascularity, enlarged submucosal glands with goblet cell metaplasia, and hypertrophy/hyperplasia of bronchial muscle. **Clinical Features:** - Severe dyspnea and wheezing result from bronchoconstriction and mucus plugging, leading to air trapping and progressive hyperinflation. - Attacks last from one to several hours and subside spontaneously or with therapy. - Intervals between attacks are typically free from overt respiratory difficulties. - **Status asthmaticus**: A severe paroxysm that does not respond to therapy, persisting for days to weeks. It is associated with hypercapnia, acidosis, and severe hypoxia, posing a potentially fatal risk. - Treatment involves glucocorticoids (anti-inflammatory), bronchodilators (beta-adrenergic drugs, leukotriene inhibitors), and agents blocking IL-4/IL-5. - **Bronchial thermoplasty** is a procedure that uses controlled thermal energy during bronchoscopy to reduce bronchial smooth muscle mass. #### Bronchiectasis - **Permanent dilation of bronchi and bronchioles** caused by the destruction of smooth muscle and elastic tissue. It typically results from or is associated with chronic necrotizing infections. - Bronchiectasis is **not a primary disorder** but is always secondary to persistent infection or obstruction. **Predisposing Conditions:** - **Bronchial obstruction**: Caused by tumors, foreign bodies, or mucus impaction. It also complicates asthma and chronic bronchitis. - **Cystic fibrosis**: Leads to widespread severe bronchiectasis due to obstruction by viscid mucus and secondary infections. - **Immunodeficiency states** (especially immunoglobulin deficiencies): Result in recurrent bacterial infections. - **Primary ciliary dyskinesia (immotile cilia syndrome)**: A rare autosomal recessive disorder characterized by inherited abnormalities of cilia, impairing mucociliary clearance and leading to persistent infections. It is also associated with infertility in males. - **Necrotizing/suppurative pneumonia**: Caused by organisms like *S. aureus* and *Klebsiella* spp. Post-tuberculosis bronchiectasis is significant in endemic areas. **Pathogenesis:** - Involves two intertwined processes: **obstruction and chronic infection**. Either can be the initiator. - Obstruction leads to impaired secretion clearance and subsequent infection. The resulting inflammatory damage causes airway dilation, which becomes irreversible. - Persistent necrotizing infection leads to poor clearance, obstruction, peribronchial fibrosis, and traction on the bronchi, ultimately causing bronchiectasis. **Morphology:** - Typically affects the lower lobes bilaterally due to the more vertical air passages. - Bronchiectasis caused by tumors or aspiration is sharply localized to a single segment. - Airways can be dilated up to **four times** their usual diameter and are visible almost to the pleural surface (normal bronchioles are not visible beyond 2–3 cm from the pleura). - Histology varies with activity and chronicity: - Active cases show intense acute and chronic inflammatory exudate, leading to desquamation of the lining epithelium and ulceration. - Organisms commonly found include staphylococci, streptococci, pneumococci, *Haemophilus influenzae*, and *Pseudomonas aeruginosa*. - During healing, the epithelium may regenerate, but dilation and scarring persist. Fibrosis of the bronchial and bronchiolar walls can occur, and abscess cavities may form. **Clinical Features:** - Severe persistent cough with expectoration of mucopurulent, sometimes fetid sputum. - Dyspnea, rhinosinusitis, and hemoptysis are common. - Episodes are often precipitated by upper respiratory tract infections or new pathogens. - Severe, widespread disease can lead to obstructive ventilatory defects, hypoxemia, hypercapnia, pulmonary hypertension, and cor pulmonale. - Complications, now less frequent, include brain abscess, amyloidosis, and cor pulmonale. ### 6. Chronic Interstitial (Restrictive, Infiltrative) Lung Diseases **Key shared features:** - Bilateral, often patchy, pulmonary fibrosis primarily affecting the alveolar walls. - Reduced lung compliance, requiring increased effort to breathe (dyspnea). - Damage to the alveolar epithelium and interstitial vasculature, leading to abnormal ventilation-perfusion (V/Q) ratios and hypoxia. - Chest radiographs show small nodules, irregular lines, or ground-glass shadows. - In advanced stages, patients develop respiratory failure, pulmonary hypertension, and cor pulmonale, with end-stage disease appearing as "honeycomb lung." - Pulmonary function tests typically show a reduced FVC with a near-normal FEV1/FVC ratio (restrictive pattern). #### Idiopathic Pulmonary Fibrosis (IPF) - A pulmonary disorder of **unknown etiology** characterized by patchy, progressive bilateral interstitial fibrosis. - Also known as **cryptogenic fibrosing alveolitis**. - Affects males more than females and is a disease of aging, rarely occurring before age 50 (and very rarely before 55). - The histologic and radiologic pattern required for diagnosis is **Usual Interstitial Pneumonia (UIP)**. - It is a **diagnosis of exclusion**, as similar changes can be seen in asbestosis and collagen vascular diseases. **Pathogenesis:** - Believed to result from repeated injury and defective repair of the alveolar epithelium in genetically predisposed individuals. - **Genetic associations**: - Germline mutations in **telomerase genes** lead to cellular senescence and a profibrotic phenotype. - A **MUC5B gene variant** (present in ~35% of affected individuals) alters mucin production. - Germline mutations in surfactant genes. - These genes are primarily expressed in lung epithelial cells, suggesting an epithelial cell abnormality is the primary initiator. - Abnormal epithelial repair leads to exuberant fibroblastic/myofibroblastic proliferation, forming **fibroblastic foci**. - Excessive activation of **TGF-β** (a profibrotic factor) drives the fibrotic process. **Morphology:** - Pleural surfaces may appear cobblestoned due to retraction of scars along interlobular septa. - The cut surface reveals firm, rubbery white areas of fibrosis, preferentially located in the lower lobes, subpleural regions, and along interlobular septa. - Histology shows **patchy interstitial fibrosis** of varying intensity, which is the hallmark. - The earliest lesions are **fibroblastic foci**, representing exuberant fibroblastic proliferation. - Over time, these areas become more collagenous and less cellular. - **Honeycomb fibrosis** develops as dense fibrosis leads to the collapse of alveolar walls and the formation of cystic spaces lined by hyperplastic type II pneumocytes or bronchiolar epithelium. - Interstitial inflammation is patchy, predominantly composed of lymphocytes, with occasional plasma cells, mast cells, and eosinophils. - Secondary pulmonary hypertensive changes are often present. **Clinical Features:** - Gradual onset of non-productive cough and progressive dyspnea. - Physical examination characteristically reveals **"dry" or "Velcro-like" crackles** during inspiration. - Late stages may present with cyanosis, cor pulmonale, and peripheral edema. - Anti-inflammatory therapies have limited efficacy as inflammation is secondary. - **Anti-fibrotic therapies** include: - **Nintedanib** (a tyrosine kinase inhibitor). - **Pirfenidone** (an inhibitor of TGF-β). - Both are approved for IPF and have shown positive clinical trial outcomes. - The **overall prognosis is poor**, with a survival of 3–5 years. Lung transplantation is the only definitive treatment. **Other Fibrosing Diseases:** - **NSIP (Non-specific Interstitial Pneumonia)**: A chronic bilateral interstitial lung disease frequently associated with collagen vascular disorders (e.g., rheumatoid arthritis). It has a **much better prognosis than IPF**. Histologically, it shows mild to moderate interstitial chronic inflammation and fibrosis that is patchy but uniform. - **Cryptogenic organizing pneumonia**: Presents with cough and dyspnea. Radiographically, it shows subpleural or peribronchial patchy airspace consolidation from intraalveolar plugs of loose organizing connective tissue. Some patients recover spontaneously, while most are treated with oral steroids. #### Pneumoconioses - Lung disorders caused by the inhalation of mineral dusts. The term has been broadened to include inorganic particulates and chemical fumes. - The three most common types are those caused by **coal dust, silica, and asbestos**. - Tobacco smoking exacerbates the effects of all inhaled mineral dusts, particularly with asbestos exposure. **Key Pathogenic Principle:** - Particles between 1–5 µm in diameter are considered most dangerous as they lodge at the bifurcation of distal airways. - Particles larger than 5–10 µm are unlikely to reach distal airways. - Particles smaller than 0.5 µm can move in and out of alveoli without substantial deposition. - Pulmonary alveolar macrophages are central to the pathogenic process; they phagocytose particles, activate the inflammasome, and produce IL-1, initiating an inflammatory response that leads to fibroblast proliferation and collagen deposition. ##### Coal Worker's Pneumoconiosis (CWP) **Spectrum of Disease:**
Answer: Model answer pending
Answer: Model answer pending
Answer: **Key Points:** - CWP is usually benign with minimal lung function decrement. - PMF can lead to increasing pulmonary dysfunction, pulmonary hypertension, and cor pulmonale. - There is **no increased frequency of lung carcinoma** in coal miners, distinguishing CWP from silicosis and asbestosis. - PMF tends to progress even without further exposure. ##### Silicosis - **The most prevalent chronic occupational disease globally**. - Caused by the inhalation of crystalline silica, with sandblasting and hard-rock mining posing the highest risk. - The most toxic forms are crystalline silica (quartz, cristobalite, tridymite), with **quartz being the most commonly implicated**. - Silica particles activate the inflammasome, leading macrophages to release IL-1, TNF, fibronectin, oxygen free radicals, and fibrogenic cytokines. - When mixed with other minerals (e.g., hematite), the fibrogenic effect of quartz is reduced. **Morphology:** - Early lesions appear as tiny, barely palpable, discrete pale-to-black nodules in the upper zones. - The **silicotic nodule** is distinctive, characterized by concentrically arranged hyalinized collagen fibers surrounding an amorphous center, giving a **"whorled" appearance of collagen**. - Polarized microscopy can reveal weakly birefringent silica particles in the center of the nodules. - As the disease progresses, nodules coalesce to form hard collagenous scars and PMF. A honeycomb pattern may develop. - Fibrotic lesions are also found in hilar lymph nodes and the pleura. **Clinical Features:** - Silicosis is often detected incidentally on routine chest radiographs in asymptomatic workers, showing fine nodularity in the upper zones. - Shortness of breath typically appears late in the course, only after PMF is present. - PMF can lead to pu